Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: Locomotor activity, drug discrimination and self-administration

Neuropharmacology

Volumn 61, Issue 4, 2011, Pages 849-856

  Meyer, A C ^a   Horton, D B ^b   Neugebauer, N M ^a   Wooters, T E ^a   Nickell, J R ^b   Dwoskin, L P ^b   Bardo, M T ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

Author keywords

Discriminative stimulus; Locomotor activity; Methamphetamine; Self administration; Tetrabenazine; Vesicular monoamine transporter 2

Indexed keywords

DOPAMINE; METHAMPHETAMINE; SEROTONIN; SEROTONIN TRANSPORTER; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN SYNAPTOSOME; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DISCRIMINATIVE STIMULUS; DOPAMINE UPTAKE; DOSE RESPONSE; DRUG DEPENDENCE TREATMENT; DRUG DISCRIMINATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENCY; DRUG SELF ADMINISTRATION; HIPPOCAMPUS; LOCOMOTION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SEROTONIN UPTAKE; SYNAPSE VESICLE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DISCRIMINATION LEARNING; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 79960026112     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.05.033     Document Type: Article

References (41)

1. N.I. Bohnen, S. Minoshima, R.A. Koeppe, P. Meyer, K. Wenette, M.R. Kilbourn, D.E. Kuhl, K.A. Frey, and R.L. Albin Decreased striatal monaminergic terminals in Huntington's disease Neurology 54 2000 1753 1759 (Pubitemid 30428401)
2. J.M. Brown, G.R. Hanson, and A.E. Fleckenstein Methamphetamine rapidly decreases vesicular dopamine uptake J. Neurochem. 74 2000 2221 2223 (Pubitemid 30217682)
3. J.M. Brown, G.R. Hanson, and A.E. Fleckenstein Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants J. Pharmacol. Exp. Ther. 296 2001 762 767 (Pubitemid 32187345)
4. L.P. Dwoskin, and P.A. Crooks A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse Biochem. Pharmacol. 63 2002 89 98 (Pubitemid 34158807)
5. J.D. Erickson, M.K.H. Schafer, T.I. Bonner, L.E. Eiden, and E. Weihe Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter Proc. Natl. Acad. Sci. U. S. A. 93 1996 5166 5171 (Pubitemid 26162890)
6. D.J. Eyerman, and B.K. Yamamoto Lobeline attenuates methamphetamine- induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum J. Pharmacol. Exp. Ther. 312 2005 160 169 (Pubitemid 40096465)
7. A.E. Fleckenstein, T.J. Volz, E.L. Riddle, J.W. Gibb, and G.R. Hanson New insights into the mechanism of action of amphetamines Annu. Rev. Pharmacol. Toxicol. 47 2007 681 698
8. K.A. Frey, R.A. Koeppe, M.R. Kilbourn, T.M. Vander Borght, R.L. Albin, S. Gilman, and D.E. Kuhl Presynaptic monoamine vesicles in Parkinson's disease and normal aging Ann. Neurol. 40 1996 873 884 (Pubitemid 27044605)
9. F. Fumagalli, R.R. Gainetdinov, Y.M. Wang, K.J. Valenzano, G.W. Miller, and M.G. Caron Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice J. Neurosci. 19 1999 2424 2431 (Pubitemid 29162392)
10. D.D. Han, and H.H. Gu Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs BMC Pharmacol. 6 2006 6
11. S.B. Harrod, L.P. Dwoskin, P.A. Crooks, J.E. Klebaur, and M.T. Bardo Lobeline attenuates d-methamphetamine self-administration in rats J. Pharmacol. Exp. Ther. 298 2001 172 179 (Pubitemid 32574524)
12. S.B. Harrod, L.P. Dwoskin, T.A. Green, B.J. Gehrke, and M.T. Bardo Lobeline does not serve as a reinforce in rats Psychopharmacology (Berl.) 165 2003 397 494
13. L.D. Johnston, P.M. O'Malley, J.G. Bachman, and J.E. Schulenberg Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2008 (NIH Publication No. 09-7401) 2009 National Institute on Drug Abuse Bethesda, MD
14. R. Jones Double-blind, Placeo-controlled, Cross-over Assessment of Intravenous Methamphetamine and Sublingual Lobeline Interactions 2007 NCT00439504. ClinicalTrials.gov
15. H. Kuribara Effects of tetrabenazine on methamphetamine-induced hyperactivity in mice are dependent on order and time-course of administration Pharmacol. Biochem. Behav. 56 1997 9 14 (Pubitemid 27016874)
16. I.S. Login, M.J. Cronin, and R.M. MacLeod Tetrabenazine has properties of a dopamine receptor antagonist Ann. Neurol. 12 1982 257 262 (Pubitemid 12053032)
17. T.J. Mantle, K.F. Tipton, and N.J. Garrett Inhibition of monoamine oxidase by amphetamine and related compounds Biochem. Pharmacol. 25 1976 2073 2077
18. +) efflux from thalamic synaptosomes Neuropharmacology 39 2000 2654 2662
19. D.K. Miller, P.A. Crooks, L. Teng, J.M. Witkin, P. Munzar, S.R. Goldberg, J.B. Acri, and L.P. Dwoskin Lobeline inhibits the neurochemical and behavioral effects of amphetamine J. Pharmacol. Exp. Ther. 296 2001 1023 1034 (Pubitemid 32187378)
20. D.K. Miller, P.A. Crooks, G. Zheng, V.P. Grinevich, S.D. Norrholm, and L.P. Dwoskin Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters J. Pharmacol. Exp. Ther. 310 2004 1035 1045 (Pubitemid 39108925)
21. T. Moran-Gates, K. Zhang, R.J. Baldessarini, and F.I. Tarazi Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder Int. J. Neuropsychopharmacol. 8 2005 439 444 (Pubitemid 41002497)
22. N.M. Neugebauer, S.B. Harrod, D.J. Stairs, P.A. Crooks, L.P. Dwoskin, and M.T. Bardo Lobelane decreases methamphetamine self-administration in rats Eur. J. Pharmacol. 571 2007 33 38 (Pubitemid 47284051)
23. J.R. Nickell, S. Krishnamurthy, S. Norrholm, G. Deaciuc, K.B. Siripurapu, G. Zheng, P.A. Crooks, and L.P. Dwoskin Lobelane inhibits methamphetamine- evoked dopamine release via inhibition of the vesicular monoamine transporter-2 J. Pharmacol. Exp. Ther. 332 2010 612 621
24. M. Prendergast, D. Podus, J. Finney, L. Greenwell, and J. Roll Contingency management for treatment of substance use disorders: a meta-analysis Addiction 101 2006 1546 1560 (Pubitemid 44527186)
25. A. Reches, R.E. Burke, C.M. Kuhn, M.N. Hassan, V.R. Jackson, and S. Fahn Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain J. Pharmacol. Exp. Ther. 225 1983 515 521 (Pubitemid 13070863)
26. M.C. Ritz, R.J. Lamb, S.R. Goldberg, and M.J. Kuhar Cocaine receptors on dopamine transporters are related to self-administration of cocaine Science 237 1987 1219 1223 (Pubitemid 17131228)
27. J.M. Roll, N.M. Petry, M.L. Stitzer, M.L. Brecht, J.M. Peirce, M.J. McCann, J. Blaine, M. MacDonald, J. DiMaria, L. Lucero, and S. Kellogg Contingency management for the treatment of methamphetamine use disorders Am. J. Psychiatry 163 2006 1993 1999 (Pubitemid 44807792)
28. S.B. Ross, and A.L. Renyi In vitro inhibition of noradrenaline-3H uptake by reserpine and tetrabenazine in mouse cerebral cortex tissues Acta Pharmacol. Toxicol. 24 1966 73 88
29. D. Scherman Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions J. Neurochem. 47 1986 331 339 (Pubitemid 16052845)
30. 3H] dihydrotetrabenazine Proc. Natl. Acad. Sci. U. S. A. 80 1983 584 588 (Pubitemid 13174647)
31. S. Shoptaw, J.D. Klausner, C.J. Reback, S. Tierney, J. Stansell, C.B. Hare, S. Gibson, M. Siever, W.D. King, U. Kao, and J. Dang A public health response to the methamphetamine epidemic: the implementation of contingency management to treat methamphetamine dependence BMC Public Health 6 2006 214
32. Substance Abuse and Mental Health Services Administration Results from the 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434) 2009 Rockville, MD
33. D. Sulzer, T.K. Chen, Y.Y. Lau, H. Kristensen, S. Rayport, and A. Ewing Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport J. Neurosci. 15 1995 4102 4108
34. N. Takahashi, L.L. Miner, I. Sora, H. Ujike, R.S. Revay, V. Kostic, V. Jackson-Lewis, S. Przedborski, and G.R. Uhl VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity Proc. Natl. Acad. Sci. U. S. A. 94 1997 9938 9943
35. 3H] dopamine uptake J. Pharmacol. Exp. Ther. 280 1997 1432 1444 (Pubitemid 27166742)
36. B.A. Vollm, I.E. de Araujo, P.J. Cowen, E.T. Rolls, M.L. Kringelbach, K.A. Smith, P. Jezzard, R.J. Heal, and P.M. Matthews Methamphetamine activates reward circuitry in drug naïve human subjects Neuropsychopharmacology 29 2004 1715 1722 (Pubitemid 39150112)
37. Y.M. Wang, R.R. Gainetdinov, F. Fumagalli, F. Xu, S.R. Jones, C.B. Bock, G.W. Miller, R.M. Wightman, and M.G. Caron Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine Neuron 19 1997 1285 1296 (Pubitemid 28030547)
38. C.J. Wilhelm, R.A. Johnson, A.J. Eshleman, and A. Janowsky Lobeline effects on tonic and methamphetamine-induced dopamine release Biochem. Pharmacol. 75 2008 1411 1415
39. T. Yero, and J.A. Rey Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington's disease-related chorea P & T 33 2008 690 694
40. G. Zheng, L.P. Dwoskin, and P.A. Crooks Vesicular monoamine transporter 2: role as a novel target for drug development AAPS J. 8 2006 E682 E692
41. G. Zheng, L.P. Dwoskin, A.G. Deaciuc, S.D. Norrholm, and P.A. Crooks Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter J. Med. Chem. 25 2005 5551 5560 (Pubitemid 41209253)